I'm not sure how this links to GB-A, that is, whether the hospitals can get funding from the Statutory Health Funds without GB-A approval.
But it highlights the scale of the opportunity and relatively rapid uptake.
If 84 hospitals do 5 each a year, that's over 400 implants. At current price it's around 8 million in revenue.
I think the Turkish distributor putting Oncosil in the same category as Lutetium treatment is very positive.
I'm not sure how this links to GB-A, that is, whether the...
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.5¢ | $4.47K | 886.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6296690 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 22890532 | 25 |
View Market Depth
| Last trade - 14.42pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 11.1 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 2050000 | ||
| Last updated 14.42pm 14/06/2024 ? | |||||
| OSL (ASX) Chart |